Cipla Share Price Today

Cipla Q2FY27 Results: Earnings call scheduled for Oct 27 at 4:00 pm

Cipla Limited will release Q2FY27 unaudited financial results on October 27, 2026. Earnings conference call scheduled for 4:00 pm IST on the same day. Transcript will be available on the company website after the call.

Maharashtra FDA cancels Cipla unit's drug sale licence over violations

Maharashtra FDA cancelled the drug sale licence of a Cipla unit. The action was taken citing alleged regulatory violations. The news emerged from a newspaper report with no further financial details.

Cipla assigned ESG rating of 68 by Niche in September

Cipla assigned an ESG rating of 68 by Niche on September 11, 2026. Rating communicated directly to NSE and BSE, not to the company. Company learned of rating via BSE alert on September 17, 2026. Disclosure made under Regulation 30 of SEBI LODR Regulations.

Macquarie keeps Cipla Outperform with target price of ₹1,675

Macquarie maintains an Outperform rating on Cipla with a target price of ₹1,675. Key observations from the Pithampur plant's previous inspection on Field Alert Report submission appear addressed. Five repeat observations remain outstanding at the Pithampur plant. Microbial contamination and adverse environmental conditions are identified as critical compliance concerns. Near-term earnings impact is expected to be limited; robust remediation and substantial CAPA evidence are required to satisfy the FDA.

Cipla secures exclusive US rights for Keytruda biosimilar QL2107

Cipla subsidiary InvaGen signs exclusive US partnership with Qilu Pharmaceutical. Deal covers licensing and supply of QL2107, a Keytruda biosimilar. Qilu handles development and supply; Cipla manages commercialization. Agreement supports Cipla's strategy to expand oncology biosimilar portfolio.

Cipla notifies NCLT order for Inzpera Healthsciences amalgamation

NCLT Mumbai approved amalgamation of Inzpera Healthsciences into Cipla. Notices sent to shareholders and unsecured creditors under Section 230(5). Stakeholders have 30 days to submit representations to the tribunal. Meetings for equity shareholders and unsecured creditors were dispensed with.